Announcement on Resolutions of the 54th Meeting of the 5th Board of Directors
Securities code: 603858 Securities abbreviation: Buchang Pharmaceutical Announcement number: 2026-119
Shandong Buchang Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 54th Meeting of the Fifth Board of Directors
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
The notice of the 54th meeting of the fifth board of directors of Shandong Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was issued on August 4, 2026. The meeting was held by communication at 13:00 on August 11, 2026. There were 12 directors who were supposed to attend the meeting and 12 directors who actually participated. The meeting was chaired by Mr. Zhao Tao, chairman of the board. The number of attendees, convening and voting methods of the meeting comply with the relevant provisions of the "Company Law of the People's Republic of China" and other laws and regulations as well as the "Articles of Association of Shandong Buchang Pharmaceutical Co., Ltd." and are legal and valid.
After deliberation by the directors present at the meeting, the meeting reviewed and approved the following proposals:
- "Proposal on Changing the Legal Representative of a Holding Subsidiary"
The company's holding subsidiary Buchang (Guangzhou) Medical Diagnostic Technology Co., Ltd. plans to change its legal representative due to business development needs.
For details, please refer to the "Announcement on the Change of the Legal Representative of the Controlled Subsidiaries" (Announcement No.: 2026-120) disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on the same day.
The proposal has been reviewed and approved by the Strategy and Investment Committee of the company's board of directors and agreed to be submitted to the board of directors for review. Voting results: 12 votes in favor, 0 votes against, and 0 abstentions.
- "Proposal on the Equity Transfer of Controlled Subsidiaries"
Li Bin, a shareholder of the company's holding subsidiary Hangzhou Buchang Jianxin Biotechnology Co., Ltd. (hereinafter referred to as "Hangzhou Buchang Jianxin"), plans to transfer his 2.00% equity stake in Hangzhou Buchang Jianxin to Yi Cui at a price of RMB 55,558.
For details, please refer to the "Announcement on the Planned Transfer of Equity Interests of the Controlled Subsidiary" (Announcement No.: 2026-121) disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on the same day.
The proposal has been reviewed and approved by the Strategy and Investment Committee of the company's board of directors and agreed to be submitted to the board of directors for review. Voting results: 12 votes in favor, 0 votes against, and 0 abstentions.
Announcement is hereby made.
Board of Directors of Shandong Buchang Pharmaceutical Co., Ltd.
August 12, 2026